Two more lawsuits were filed against GlaxoSmithKline this week, adding to a string of actions against the pharmaceutical industry for alleged efforts to keep generic competitors out of the marketplace. New York City charged federal antitrust violations in suits filed in Virginia and Pennsylvania against GSK, charging the company with "evergreening" its Paxil and Augmentin patents. GSK denied any improprieties, saying the suit is part of a "political climate" that portrays pharmaceutical companies as trying to keep drug prices high.

Full Story:

Related Summaries